Pancreatic Cancer Research

ResearcherUniversité de BordeauxActive in the last 2 years

Christophe Laurent

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2449-6349; OpenAlex author ID A5039130569. Sources: OpenAlex.

Their work

Papers
17 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
55
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: 4 papers · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 5 papers

Papers 17

  1. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  2. Metallic trace elements in pancreatic tissue are associated with higher risk of pancreatic adenocarcinoma - METAPANDA study. Co-author DOI 10.1016/j.pan.2025.03.006↗
  3. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  4. Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter T… Co-author DOI 10.1245/s10434-024-16735-2↗
  5. Preoperative Prognostic Factors in Resectable Pancreatic Cancer: State of the Art and Prospects. Co-author DOI 10.1245/s10434-025-17062-w↗
  6. Influence of pancreatic fistula on survival after upfront pancreatoduodenectomy for pancreatic ductal adenocarcinoma: multicentre retrospective study. Co-author DOI 10.1093/bjsopen/zrae125↗
  7. Response to the comment of V. Vashney and A. Swami for "pre-operative embolization of a replaced right hepatic artery before pancreaticoduodenectomy for pancre… Last author DOI 10.1016/j.hpb.2021.11.002↗
  8. KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence. Co-author DOI 10.1038/s41598-022-07004-x↗
  9. Does pre-operative embolization of a replaced right hepatic artery before pancreaticoduodenectomy for pancreatic adenocarcinoma affect postoperative morbidity … Last author DOI 10.1016/j.hpb.2021.04.003↗
  10. Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery. Co-author DOI 10.1080/0284186x.2021.1944662↗
  11. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre. Co-author DOI 10.1016/j.dld.2019.03.004↗
  12. CD63-GPC1-Positive Exosomes Coupled with CA19-9 Offer Good Diagnostic Potential for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.tranon.2019.07.009↗
  13. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRE… Co-author DOI 10.1245/s10434-018-6931-6↗
  14. High Clinical Value of Liquid Biopsy to Detect Circulating Tumor Cells and Tumor Exosomes in Pancreatic Ductal Adenocarcinoma Patients Eligible for Up-Front Su… Co-author DOI 10.3390/cancers11111656↗
  15. Pancreatic adenocarcinoma: A simple CT score for predicting margin-positive resection in patients with resectable disease. Co-author DOI 10.1016/j.ejrad.2017.06.028↗
  16. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-… Co-author DOI 10.1245/s10434-015-4783-x↗
  17. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy. Co-author DOI 10.1148/radiol.14132914↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. L. Chiche · 10 shared papers, 2014–2024 · strength 1.14
  2. Sandrine Dabernat · 5 shared papers, 2019–2025 · strength 0.68
  3. Arthur Marichez · 3 shared papers, 2021–2025 · strength 0.63
  4. Jean‐Frédéric Blanc · 5 shared papers, 2014–2025 · strength 0.54
  5. Étienne Buscail · 5 shared papers, 2019–2022 · strength 0.50
  6. Jonathan Garnier · 3 shared papers, 2021–2025 · strength 0.46
  7. V. Vendrely · 6 shared papers, 2014–2021 · strength 0.45
  8. Samuel Amintas · 2 shared papers, 2022–2025 · strength 0.44
  9. Olivıer Turrini · 4 shared papers, 2015–2024 · strength 0.42
  10. Alain Sauvanet Sauvanet · 3 shared papers, 2019–2025 · strength 0.41
  11. António Sá Cunha · 5 shared papers, 2014–2024 · strength 0.40
  12. Mehdi Boubaddi · 1 shared paper, 2025 · strength 0.28
  13. Ugo Marchèse · 2 shared papers, 2021–2025 · strength 0.28
  14. Sandra Mounicou · 1 shared paper, 2025 · strength 0.27
  15. Mireille Simon · 1 shared paper, 2025 · strength 0.27
  16. Jean‐Robert Delpéro · 2 shared papers, 2019–2021 · strength 0.20
  17. Claudia Pouypoudat · 2 shared papers, 2019–2021 · strength 0.19
  18. Christophe Cassinotto · 3 shared papers, 2014–2019 · strength 0.19
  19. Fanny Castanet · 1 shared paper, 2024 · strength 0.18
  20. Fabrice Muscari · 1 shared paper, 2024 · strength 0.18
  21. Charlotte Maulat · 1 shared paper, 2024 · strength 0.18
  22. Gabriella Pittau · 1 shared paper, 2024 · strength 0.18
  23. Lilian Schwartz · 1 shared paper, 2025 · strength 0.16
  24. Julie Navez · 1 shared paper, 2025 · strength 0.16
  25. Charles de Ponthaud · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.